



Contacts: Meg McGilley
Chief Financial Officer
(858) 480-0402

Rob Whetstone
PondelWilkinson Inc.
(310) 279-5963

Somaxon Pharmaceuticals to Present at the Needham & Co. 7th Annual Biotechnology and Medical Technology Conference

SAN DIEGO, CA – (June 6, 2008) – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Susan Dubé, senior vice president, corporate development, will present a company overview at the Needham 7th Annual Biotechnology and Medical Technology Conference at the New York Palace Hotel in New York City, on Thursday, June 12, 2008 at 1:00 p.m. ET (10:00 a.m. PT).

A live webcast of the presentation will be available through the Investor Relations section of the company's website under Event Scheduler at www.somaxon.com. The webcast will be archived and accessible for at least 14 days.

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENORTM (doxepin HCl) for the treatment of insomnia. The FDA recently notified Somaxon that it accepted the NDA for SILENORTM for review as of March 31, 2008. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Somaxon expects that the FDA will complete its review and provide an action letter to the company with respect to the NDA by December 1, 2008. For more information, please visit the company's web site at www.somaxon.com.

###